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ABSTRACT
Biologic drugs have revolutionized the treatment of many life-threatening and rare illnesses such as cancer and autoimmune diseases. Biologics are 
broadly referred as substances that are produced by living cells and are used in the treatment, prevention, or diagnosis of diseases. They include a 
wide range of substances, such as genetic material, antibodies, vaccines, or processes which act by influencing cellular processes that block disease or 
affect diseased cells. Biologics have become striking treatment options and the size of the market has grown hastily. It is expected that by 2023, most 
of the patents will expire in the European Union opening a large potential market. Keeping this in mind, the ability to launch substitutes to original 
biologics, also known as biosimilars, presents many opportunities to generic companies. The field of biosimilars seems to be “breaking” the traditional 
division between the creations of innovative NCE-based medicines by research-based companies, on the one hand, and, on the other hand, mapping of 
these medicines by the generic companies. The field of biosimilars so far presents some considerable challenges, namely, regulatory, safety, economic, 
and legal which are still being debated and discussed in different forums. In this article, we have tried to summarize the general principles and 
regulations governing the development of biosimilars by regulatory authorities such as the World Health Organization, European Medicines Agency, 
US Food and Drug Administration, and Health Canada. Furthermore, we have tried to throw some light on the opportunities, challenges, and current 
scenarios pertaining to biosimilars.
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INTRODUCTION
Biotechnology has coined the development of treatments for a 
variety of serious, rare, and severe diseases including cancers, heart 
attacks, stroke, multiple sclerosis, diabetes, rheumatoid arthritis, and 
autoimmune diseases. Numerous biological medicinal products have 
reached their expiration in the coming decade and with this expiry, 
similar biological medicinal products (SBMPs), or biosimilar medicinal 
products, “biosimilars” as they are now commonly called are being 
developed and a number of them are already available in different 
markets around the globe [1].
A biosimilar contains a version of the active substance of an already 
authorized original biological medicinal product (reference medicinal 
product [RMP]), demonstrates similarity to the RMP in terms of quality 
characteristics, biological activity, safety, and efficacy based on an 
inclusive comparability exercise [2].
There is a huge opportunity for the development of biosimilars in the 
near future because of the favoring adoption of regulatory guidelines 
by different countries. The specific product guidelines pertaining 
to biosimilars are also available and include filgrastim; epoetins; 
growth hormones; insulin; aloha-interferons; beta-interferons; 
monoclonal antibodies; follitropin; and low-molecular-weight 
heparins [3]. The United State Food Drug and Administration (FDA) 
evaluation of biosimilarity must reflect on the product’s complexity, its 
formulation, its stability, and the efficacy of biochemical and functional 
characterizations and incorporate these factors into a risk-based 
approach. The understanding of the clinical effect of a biologic and the 
level of clinical information available on it will also affect the evaluation 
of risk, and the manufacturing processes may set up potential variants 
or impurities that could affect risk [4].
So far, the field of biosimilars presents several important challenges 
using safety, regulatory, legal, and economic which are the topics of 
discussion across the world [5].
DEFINING BIOSIMILARS
Different regulatory bodies have coined different definitions to describe 
the term “Biosimilars.” Each regulatory body portrays a slight different 
perspective than the other which is quite evident through their 
definitions. Some of the definitions by the leaders in similar medicinal 
products are mentioned:
World Health Organization (WHO)
“A biotherapeutic product which is similar in terms of quality, 
safety, and efficacy to an already licensed reference biotherapeutic 
product” [6].
US Food and Drug Administration (FDA)
FDA defines “biosimilarity to mean that the biological product is highly 
similar to the reference product notwithstanding minor differences 
in clinically inactive components” and so on “there are no clinically 
meaningful differences between the biological product and the 
reference product in terms of the safety, purity, and potency of the 
product” [7].
European Medicines Agency (EMA)
A biosimilar medicine is a “biological medicine that is developed to be 
similar to an existing biological medicine.” Biosimilars are not the same 
as generics, which have simpler chemical structures and are considered 
to be identical to their reference medicines. The active substance of a 
biosimilar and its reference medicine is essentially the same biological 
substance, though there may be minor differences due to their complex 
nature and production methods [8].
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Therapeutic Goods Administration (TGA)
“A biosimilar or SBMP is a version of an already registered biological 
medicine that has a demonstrable similarity in physicochemical, 
biological, and immunological characteristics, efficacy, and safety, based 
on comprehensive comparability studies [9].”
Health Canada
“A biosimilar biologic drug, or biosimilar, is a biologic drug that is highly 
similar to a biologic drug that was already authorized for sale. There 
are no expected clinically meaningful differences in efficacy and safety 
between a biosimilar and the biologic drug that was already authorized 
for sale [10].”
AWAITING OPPORTUNITIES AND CURRENT SCENARIOS
A very huge potential awaits the development of the biosimilars because 
the exclusive rights (patents and other data protection) for several 
biological medicinal products have reached their expiration and many 
more will expire in the coming decade. In the European Union (EU), 
by the year 2019, around 14 innovative biological products had been 
deprived of their market exclusivity as an orphan drug. By the end of 
2029, 34 other innovative biologics are ready to join them. It is expected 
that by 2023, most of the patents will expire in the EU opening a large 
potential market [11]. In the year 2026, the global biosimilars market is 
expected to reach approximately USD 44.7 billion from USD 15.6 billion 
(in 2021) in just a short span of 5 years at a 23.5% of CAGR. This market 
growth is driven by the increasing incidence of chronic diseases and 
the hope which lies in the similar medicinal products largely due to 
their cost-effectiveness and the short development span compared 
to the RMP. On an average, these products may employ 70% less cost 
and 30–50% less development time than their biologic originals saving 
almost $44 billion health-care costs in the EU itself. The rising incidence 
of chronic diseases and cancer in the geriatric population was credited 
for the monoclonal antibodies segment gathering the largest share of 
27.5% in the biosimilars market. The oncology segment is the largest 
due to which the cancer treatment is more accessible and affordable. 
The prevailing burden of cancer around the globe needs cost-effective 
treatment options which can be made accessible by the huge biosimilars 
market. This has led to increase in investments by major biological 
pharma companies in this domain of biosimilars. The growing markets 
include Africa, North America, Asia Pacific Latin America, Europe, 
and Middle East. Among all, the Asia-Pacific market is expected to be 
credited as the fastest-growing market during the period 2021–2026 
due to the less stringent regulations, many emerging players and 
the increasing cooperation among regional and leading players for 
commercialization, manufacture, and development of biosimilars [12].
DEVELOPING BIOSIMILARS
Biotechnology uses living systems (plant or else animal cells, bacteria, 
viruses, and yeast) and modern technologies to generate biological 
medicines to treat diseases and genetic disorders in humans. Most of 
them, but not all biological medicines, are made using genetically modified 
cells. Each manufacturer has its own unique cell lines and develops its 
own proprietary (unique) manufacturing processes [13]. The production 
of biological medicines involves processes such as fermentation and 
purification. Even very small changes to these manufacturing processes 
like minor variations during production, for example, temperature 
variations, can result in considerable changes in the clinical properties of 
the biological medicine produced. It is very important to precisely control 
the manufacturing processes and the situation inside a production 
facility, to obtain consistent results and to assurance the safety and 
efficacy of the final product. The production of biological medicines is a 
complex process which requires a very high level of technical expertise 
with typically about 250 in-process tests being conducted compared to 
about 50 tests for a small molecule medicine [1].
Characterization of Biosimilars
To ensure assuring global quality, safety, and efficacy of biotherapeutics, 
the WHO provides globally accepted norms and standards for the 
evaluation of these products. Written standards established through 
the Expert Committee on Biological Standardization (ECBS) serve like a 
basis for setting national requirements for production, quality control, 
and overall regulation of biological medicines [7]. Comprehensive 
characterization of both Reference Biotherapeutic Product (RBP) 
and Similar Biotherapeutic Product (SBP) should be carried out 
using appropriate, biochemical, biophysical, and biological analytical 
techniques [14]. Below mentioned criteria shall be considered while 
conducting the comparability exercise:
Physicochemical properties
The physicochemical characterization ideally should include the 
determination of higher order (such as secondary/tertiary/quaternary) 
and primary structure using appropriate analytical methods (e.g., mass 
spectrometry and nuclear magnetic resonance) and other biophysical 
properties. Structural heterogeneity inherently occurs in proteins 
due to the biosynthesis process such as SBP and RBP which are likely 
to contain a mixture of these post-translationally modified forms. 
Appropriate efforts should be made to investigate, identify, and quantify 
these forms [15,16].
Biological activity
Biological activity is the specific ability or capability of the product 
to achieve a defined biological effect. Biological assay reflects the 
mechanism of action of a protein and therefore serves as a bridge to 
clinical activity. A biological assay is a quality measure of the “function” 
of the protein product and can be used to determine whether a product 
variant has the appropriate level of activity (i.e., a product-related 
substance) or is inactive [17,18].
Immunochemical properties
Immunochemical properties confirm that the SBP is comparable to 
the RBP in terms of specificity, affinity, binding kinetics, and functional 
activity, where relevant [19].
Impurities
Due to the partial access to all necessary information on the 
manufacturing process in addition to the drug substance of the originator 
product, it is recognized that the evaluation of similarity of the impurity 
profiles between SBP and RBP will be generally difficult. Yet product-
related and process impurities should be identified, then quantified by 
biochemical and compared between the RBP and SBP. Some differences 
may be predictable because the proteins are produced by different 
manufacturing processes. If significant differences are observed in the 
impurity profile between the SBP and the RBP, their potential impact on 
efficacy and safety, including immunogenicity, must be evaluated [20,21].
Analytical techniques
The methods should separate and analyze different variants of 
the product based on different underlying chemical, physical, and 
biological properties of protein molecules. For example, ion-exchange 
chromatography, isoelectric focusing, and capillary electrophoresis 
all separate proteins based on charge, but they act so under different 
conditions and based on different physicochemical properties. The 
parameters which evaluate biosimilars should be measured while 
making a determination of similarity between a SBP and a RBP, depicted 
in Table 1 [22,23].
REGULATIONS AND PRINCIPLES GOVERNING BIOSIMILARS
For the assessment of biosimilars, regulatory requirements from 
different regions such as the WHO, EU, US, and Asian Pacific Region are 
almost similar with specific guideline.
WHO
In the year 2007, the WHO formally recognized the need for overall 
regulation and the guidance for their evaluation. “Guidelines on 
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Evaluation of SBPs” were developed and adopted by the 60th meeting 
of the WHO ECBS in 2009. The Annex 2 for the same guideline was also 
released by the Expert committee in its Sixtieth report in 2013 [24]. The 
guideline aims to provide globally acceptable principles for licensing 
SBPs that are claimed to be similar to the reference products (licensed 
before based on a full licensing dossier). The scope of the guidelines 
includes well-established and well-characterized biotherapeutic 
products that have been marketed for a suitable period of time with a 
proven quality, efficacy, and safety, such as recombinant DNA-derived 
therapeutic proteins. Manufacturers are required to submit a full quality 
dossier which includes a demonstration of robust and manufacture of 
the product, consistent complete characterization of the product, and 
the comparability exercise between the SBP and the RBP in the quality 
part, which together serve as the basis for the possible reduction in data 
requirement in the non-clinical and clinical development. The WHO 
guidelines on evaluating SBPs represent an important step forward in 
the global harmonization for the evaluation and regulation of biosimilar 
products, and provide clear guidance for both regulatory bodies and the 
pharmaceutical industry [25]. On March 1, 2016, draft guideline referred 
to as “Guideline on Evaluation of Monoclonal Antibodies as SBPs was 
released [26]. The outcome of which was then published in the WHO 
Technical Report Series, 2017, by the WHO ECBS in the 67th report [27]. 
In the year 2019, the WHO prequalified its first biosimilar medicine 
known as trastuzumab which is a monoclonal antibody responsible for 
treating breast cancer in women [28].
EU (EMA)
The EU has pioneered in the development of a regulatory system for 
biosimilar products by approving the first biosimilar in the year 2006. 
The EMA began formal consideration of scientific issues for biosimilar 
products as early as January 2001, then an ad hoc working group had 
discussed the comparability of medicinal products (that contains 
biotechnology derived proteins as active substances) [29]. In the year 
2003, the European Commission had amended the provisions of the 
EU legislation governing requirements for marketing authorization 
applications (MAA) for medicinal products and ultimately established 
a new category of applications for “similar biological medicinal 
products [30].” In 2005, the EMA issued a general guideline on similar 
biological medicinal products, to introduce the concept of similar 
biological medicinal products, to outline the basic principles to be 
applied, and to provide applicants with a “user guide,” showing where 
to find relevant scientific information [29,31]. The revised version of 
this guideline was first published in 2014 [2].
EU has taken an evidence-based and thoughtful approach, and has 
established a well-documented regulatory and legal pathway for the 
approval of biosimilar products different from the generic pathway. 
To grant a biosimilar product, the EMA requires justified and 
comprehensible comparability studies between the reference products 
and biosimilar on the non-clinical, quality, and clinical level, and is well-
explained in detail in the EMA guidelines. In the EU, the approval pathway 
of biosimilar products is based on the case-by-case reviews, due to the 
diversity and complexity of the biologic products. Therefore, besides 
the general guidelines, EMA also developed product class-specific 
guidelines on clinical and non-clinical studies. The approval pathway 
is now seen as one of the gold standards for authorizing biosimilar 
products among various countries. In the year 2006, the “Guideline 
on Similar Biological Medicinal Products Containing Biotechnology-
derived Proteins as Active Substance: Quality Issues” was adopted by the 
CHMP, which addressed the requirements regarding the comparability 
exercises for quality, manufacturing processes, physicochemical 
characterization, purity, analytical methods, biological activity, and 
specifications of the similar biological medicinal product [32]. The 
revised version of this guideline was published in the year 2014 [15]. 
In 2011, EMA also issued a concept paper based on the revision of 
the guideline “Guideline on Similar Biological Medicinal Products 
Table 1: Parameters for the evaluation of biosimilars
Parameters Characteristics Test for comparability
Physicochemical properties Primary structure
Secondary structure
Tertiary and quaternary structure
Edman degradation, peptide mapping with (LC-MS), 
C-terminal sequencing, Amino acid analysis. far UV, CD, 
NMR, FTIR, X-ray crystallography
Molecular mass Mass spectrometry – MALDI and ESI-MS, 
ultracentrifugation, SDS-PAGE
Isoforms Isoelectric focusing, capillary electrophoresis, IE-HPLC
Crystal structure Microscopy (where crystal structure is necessary for 
action, e.g., protamine zinc insulin)
Sugar composition and linkage Quantitative monosaccharide analysis (for polysaccharide 
biological medicines like heparin)
Biological activity In vivo activity Measuring therapeutic effect in animals
In vitro activity Cell proliferation or inhibition of proliferation, cell 
senescence, and measurable changes in cell size or content 
(e.g., mRNA)
Enzyme assays Assay for potency
Receptor-binding assays Assay for action
Chromogenic or turbidometric techniques Promotion or inhibition of coagulation
Content, purity, and impurity profile Protein content Protein assay (e.g., Kjeldahl, Lowry, and Bradford), 
Absorbance at 280 or 230 nm, HPLC, SDS-PAGE
Purity HPLC, RP-HPLC, size exclusion – HPLC, ion exchange – 
HPLC, SDS-PAGE
Impurities – process derived DNA – Threshold® Host protein – [ELISA]
Cell culture – ELISA
Leachates – HPLC, GC
Protein A-ELISA
Impurities – product derived Oxidized – RP-HPLC
Deamidated – RP-HPLC
N-terminal cyclisation – LC-MS
Phosphorylation – IE-HPLC
NMR: Nuclear magnetic resonance, UV: Ultraviolet, CD: Circular dichroism, FTIR: Fourier transform infrared, MALDI: Matrix-assisted laser desorption ionization, ESI-MS: 
Electrospray ionization mass spectrometry, SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis, IE-HPLC: Ion exchange high-performance liquid 
chromatography, ELISA: Enzyme-linked immunosorbent assay
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Containing Biotechnology-derived Proteins as Active Substance: Non-
Clinical and Clinical Issues [31,33].” The current effective version was 
released in 2015 [14].
General principles governing the development of biosimilars in 
the EU [2]
A biological medicinal product containing a version of the active 
ingredient of an already authorized biological medicinal product also 
known as the RMP. In European Economic Area (EEA), the MAA is 
granted authorization after the demonstration of similar nature of the 
two products, the chosen (RMP) and the biological medicinal product. 
Comparability studies play an important role in generating evidence 
conforming the similar nature in respect to efficacy, quality, biological 
activity, and safety of the chosen RMP and our similar biological 
medicinal product.
Applying the biosimilar approach
The success to developing a biosimilar relies solely on demonstrating 
similarity between the two products and generating similarity at the 
level of biological and physiochemical characteristics. The knowledge to 
interpret the differences between the RMP and the biological medicinal 
product is equally essential. It’s the complexity of the biosimilars that 
it requires the comprehensive comparability (ICH Q5E) unlike the 
standard generic approach of demonstrating bioequivalence as in most 
chemically derived medicinal products. This approach is most likely 
to yield success in products that are highly purified and thus can be 
thoroughly characterized. The things that need to be taken care are as 
follows:
•	 Active ingredient of a biosimilar has to be similar in respect to 
biological and molecular characters to the chosen RMP
•	 Rout of administration and posology to be same as of the RMP
•	 If any deviations from the RMP are present in regard to pharmaceutical 
form, strength, formulation excipients, or presentation require 
proper justification. Additional data may be provided and no 
compromise should be made on safety
•	 Changes to improve efficacy are not too compatible with the 
biosimilar approach, however, still any differences that could have 
an advantage such as lower immunogenicity and levels of impurities 
(safety aspect) should be addressed but still may not preclude 
biosimilarity
•	 Once biosimilarity has been demonstrated in one indication, 
extrapolation can be used for other indications of RMP with proper 
justification
•	 No regulatory requirement to once again demonstrates the 
biosimilarity against the RMP once the MAA has been granted
•	 In regard to the quality data, biosimilars need to fulfill the 
requirements for Module 3 (defined in Annex 1 to Directive 2001/83/
EC). Furthermore, the technical requirements in the European 
Pharmacopeia and other requirements laid down in the CHMP and 
ICH guidelines need to be fulfilled
•	 All appropriate measures are required to be taken to clearly identify 
any biological medicinal product which can show adverse drug 
reaction with due regards to its batch number and brand name to 
support pharmacovigilance monitoring (Article 102(e) of Directive 
2001/83/EC)
•	 Safety and efficacy comparable data of a biosimilar and chosen 
RMP have to be justified or demonstrated in accordance with 
requirements laid in Directive 2001/83/EC. Product-specific classes 
such as recombinant granulocyte-colony-stimulating factor [34], 
low molecular heparin [35], recombinant human insulin and its 
analogs [36], interferon beta [37], monoclonal antibodies [38], 
recombinant erythropoietins [25], recombinant follicle-stimulating 
hormone [39], and somatropin [40] have defined guidelines and can 
be referred. Apart from these products, the agency can be contacted 
for any other product query.
Choosing the RMP
The chosen RMP must be authorized in the EEA and should be used 
in the comparability studies of safety, quality, and efficacy during the 
development of biosimilar to generate coherent conclusions and data. 
In some cases, it may also be possible to compare the biosimilar in 
various in vivo non-clinical studies (wherever necessary) and clinical 
studies with a non-EEA authorized comparator (adequate data to 
scientifically justify and establish a bridge to the EEA authorized RMP) 
only if the product is authorized by the regulatory authority with a 
similar regulatory and scientific standard as that of the EMA (e.g., 
ICH countries).The bridging data would include data from analytical 
studies comparing all the three products, namely, EEA authorized RMP, 
non-EEA authorized RMP, and the biological medicinal product. It may 
also include data from studies such as clinical PK and/or PD bridging 
studies for the three products. The acceptability decision will be taken 
case by case and is recommended to be discussed with the regulatory 
agency. The final decision will still be made during the assessment 
of the application at the time of submission. Furthermore, it is the 
responsibility of the applicant to establish the comparability between 
both the EEA authorized RMP and the non-EEA authorized RMP.
Demonstration of biosimilar quality comparability studies, side-by-
side analysis of biosimilar product from the site to commercial scale 
with EEA authorized RMP is necessary required. For the development 
of Quality Target Product Profile, combined use of EEA authorized and 
non-EEA authorized RMP is acceptable.
Principles to establish the biosimilarity
Any difference observed in the physiochemical and biological 
characteristics of the chosen RMP and biological medicinal products 
and their potential impact on the efficacy and safety should be duly 
justified.
The stepwise approach is adapted initiating with the comprehensive 
characterization of biological and physiochemical properties. Further, 
the nature and extent of the clinical studies and non-clinical in vivo 
studies would depend on the evidences obtained while the robustness 
of biological, physiochemical, and non-clinical in vitro characterization 
was being performed. Clinical studies are performed to address the 
slight variability at the previous steps and confirm the comparability 
clinical performances of the chosen RMP and our similar medicinal 
product, however, clinical data can never be used to justify the 
substantial differences between the two products at the level of quality.
The comparability studies need to be sensitive in regards to conduct, 
design, population, and/or endpoints to detect any relevant differences 
between the RMP and biosimilar. In specific cases, where the similar 
safety and efficacy can be deduced from the biological activity/potency, 
physiochemical characteristics, and PK and/or PD profiles, clinical 
trials are not mandatory. Here, the nature of excipients and clinical 
trials should not give rise to any potential concerns. It is advisable to 
discuss such approaches with the regulatory agencies.
In cases where the biosimilar comparability exercise shows that 
relevant differences between the RMP and intended biosimilar making 
it unlikely that the intended biosimilar will be established eventually, 
therefore, a stand-alone development for supporting a full MAA should 
be considered instead.
The biosimilar products approved in the EU by EMA in the year 2021 
are depicted in Table 2.
Australia (TGA)
International regulators such as the TGA directly apply the principles 
that are laid down by the EU legislation for the approval and 
development of biosimilars. TGA directly refers to the already released 
guidelines by EU for different aspects such as quality, clinical and non-
clinical studies, establishing comparability and for different products, 
and their specific guidelines [49].
US (FDA)
Approval of follow-on biologics in the US based on the current 
regulations depends on whether the biologic product is licensed under 
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the United States Public Health Service Act or approved under the 
United States Food, Drug, and Cosmetic Act. For those biologic drugs 
marketed under the PHS Act, the BPCI Act passed by the US Congress 
on March 23, 2010, amends the PHS Act to establish an abbreviated 
approval pathway for biological products which are interchangeable or 
highly similar with a FDA authorized biologic drug while giving FDA the 
authority to approve follow-on biologics under the section 351(k) of 
the PHS Act [50].
FDA has established three committees to ensure consistency in the 
FDA’s regulatory approach of follow-on biologics. The committees are 
the Center for Biologics Evaluation and Research (CBER)/Center for 
Drug Evaluation and Research (CDER), Biosimilar Implementation 
Committee, CBER Biosimilar Review Committee (BRC), and the CDER 
BRC. The CDER/CBER BRC will focus on the cross-center policy issues 
related to the implementation of the BPCI Act. The CDER BRC and 
CBER BRC are responsible for considering requests of applicants 
for advice about proposed development programs for biosimilar 
products, reviewing Biologic License Applications (BLAs) that are 
submitted under the 351(k) section of the PHS Act, and managing 
related issues. Thus, the review process steps of CDER BRC and CBER 
BRC include: (1) Applicant submits request for advice, (2) internal 
review team meeting, (3) internal CDER BRC (CBER BRC) meeting, 
(4) internal post-BRC meeting, and (5) applicant meeting with CDER 
(CBER) [7].
General principles governing the development of biosimilars in 
the US [51-58]
Biological products are regulated by the FDA and are used to 
prevent, diagnose, cure, and treat medical conditions and diseases. 
All the biological products approved by FDA, including biosimilar, 
interchangeable, and reference products, undergo a rigorous 
assessment to ensure their safety, efficacy, and quality for patient 
use. A single biological product which is already approved by FDA 
and against which a proposed biosimilar product can be compared is 
referred to as reference product. A reference product receives approval 
in a “standalone” application and it must contain all information and 
data necessary to demonstrate its effectiveness and safety. The data 
necessary to demonstrate the effectiveness and safety of a reference 
product will generally also include clinical trials for the indications 
being sought by the applicant/manufacturer.
Applying the biosimilar approach
Biosimilar is highly similar to and does not possess any clinically meaningful 
differences in purity, safety, and potency (effectiveness and safety) from, 
an existing reference product already approved by FDA. The aim of a 
biosimilar development program is to establish while demonstrating 
biosimilarity between the reference product and the proposed biosimilar 
product and, not just independently establish the effectiveness and safety 
of the proposed product. This generally includes data from:
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•	 Analytical studies to demonstrate that the proposed biological 
product is highly similar to the FDA-approved reference product, 
nevertheless the minute differences in clinically inactive 
components
•	 Animal studies which would also include an assessment of toxicity
•	 Clinical study or studies that are sufficient to demonstrate potency, 
safety, and purity of the biosimilar product for one or more of the 
disease indications for which the reference product is already 
licensed. Typically includes pharmacokinetic (PK), immunogenicity, 
and sometimes pharmacodynamic (PD) assessment. It may include 
a comparative clinical study too.
Apart from the data listed above, an interchangeable product application 
must be submitted including data or information demonstrating that:
•	 The same clinical results are expected as that of the reference product 
to be demonstrated in the proposed interchangeable product in any 
given patient
•	 A product which is administered more than once to a patient, 
switching between the reference product and the proposed 
interchangeable product does not decrease effectiveness or increase 
safety risks in comparison to using just the reference product without 
any such switching between products.
Choosing the reference product
A single biological product which is already approved by FDA and 
against which a proposed biosimilar product can be compared is 
referred to as reference product. It is approved based on, among other 
things, a full complement of effectiveness and safety data. A proposed 
biosimilar product is evaluated and compared against a reference 
product to ensure the high similarity and no clinically meaningful 
differences.
Principles to establish the biosimilarity
The applicant/manufacturer of a proposed biosimilar product is 
responsible for generating a set of data comparing the proposed product 
to the approved reference product to demonstrate biosimilarity.
•	 The comparative data are evaluated and generated in a stepwise 
manner that begins with detailed analytical (functional and 
structural) comparison and characterization of the products, 
followed by the animal studies if necessary and then move on to the 
comparative clinical studies
•	 Subsequently, rather than producing the same full profile of clinical 
and non-clinical data as that of the reference product, an applicant/
manufacturer which shows its biosimilar product has no clinically 
meaningful differences and is highly similar to the approved reference 
product, might also rely in part on FDA’s former determination of 
effectiveness and safety for the approval of reference product. 
Implying that biosimilar manufacturers do not need to perform as 
many lengthy and expensive clinical trials, possibly leading to a faster 
access to approval of these products, reduced costs for patients and 
additional therapeutic options
•	 FDA assesses each biosimilar on a case-to-case basis to determine 
which data are required to establish biosimilarity and which 
elements can be waived off if deemed scientifically fitting.
Many other factors can help alter the data requirements for different 
biosimilar applications like:
•	 The robustness and strength of the comparative analytical studies 
that show similar functions and structure between the reference 
product and the proposed biosimilar. For instance, analytical 
similarity data displaying very minor analytical differences might 
provide a strong support and reflect that the product is highly similar
Table 3: List of FDA approved biosimilar and interchangeable products for the year 2020 and 2021 [59]
Date 
approval
BLA number Applicant Proprietary 
name


























Pegfilgrastim-apgf 6 mg/0.6 
mL






Hospira Inc., a 
Pfizer Company

















Hulio [63] Adalimumab-fkjp 40 mg/0.8 
mL; 20 
mg/0.4 mL























































Byooviz [67] Ranibizumab-nuna 10 mg/mL Injection Intravitreal Single-dose 
vial
BLA: Biologic License Application
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•	 How similar the PD and PK profiles are between the reference product 
and the proposed biosimilar
• Pre-existing information regarding the safety profile of the FDA-
approved reference product. For instance, if it is known that patients 
might develop immune responses with the reference product, FDA 
will require a more rigorous assessment of immune responses for 
the biosimilar too.
The biosimilar and interchangeable products approved in the US by 
FDA in the year 2020 and 2021 are depicted in Table 3.
Canada (Health Canada)
The federal regulatory authority of Canada, the Health Canada 
evaluates the efficacy, safety, and quality of drugs available in Canada. 
It also recognizes it with the expiration of patents for biologic drugs 
as the manufacturers may be interested in pursuing consequent entry 
versions of these biologic drugs, which are called Subsequent Entry 
Biologics (SEB) in Canada. In the year 2010, Health Canada issued the 
“Guidance for Sponsors: Information and Submission Requirements 
for Subsequent Entry Biologics (SEBs),” the objective of which was 
to provide guidance on how to satisfy the regulatory requirements 
in Canada under the Food and Drugs Act and Regulations for the 
authorization of SEB [10]. The key principles that are used by Health 
Canada to evaluate the similar medicinal product/biosimilar align with 
other regulatory agencies as that of EMA, FDA, and the WHO [68].
The harmonized scope and requirements across different markets are 
depicted in Table 4.
CHALLENGES AHEAD
Biosimilars complex development presents challenges at every next 
level, from analytical assays demonstrating comparability to selection 
of a manufacturing platform, to clinical testing and in vivo testing, 
post-marketing surveillance, and even market access. One of the 
challenges for the development of such assays is the procurement 
of high-quality assay reagents, such as target antigens or coating 
antibodies. In some cases, the assays performed by the originator 
company may be unknown, antiquated, or even patent protected. 
Another major challenge is the significance of the glycosylation 
state of the biosimilar in comparison to the reference product. This 
ultimately can have a major impact on the similarity of calibration 
curves of the biosimilar and reference product. The glycosylation 
state of a biosimilar can be influenced by many different steps in the 
production process used to generate a given molecule, for example, 
cell culture conditions, and manufacturing or finishing processes. 
Some other challenges that were revealed in a recent WHO survey 
(2019–2020) are the lack of resources, insufficient/unavailable 
reference products in any country, difficulties with practice of 
naming of biosimilars and interchangeability, and the problem with 
the quality of biosimilars [69-71].
CONCLUSION
The biologics have rekindled hope in the treatment of various rare and 
life-threatening diseases such as cancer and autoimmune diseases. 
With the patent expiration going to take place for many products 
in the coming years, the market for their substitutes also known as 
biosimilars continues to grow opening a whole new domain. Compared 
to the NCE-based drugs, the development of similar medicinal 
product is complex and requires specific guidelines ensuring safety 
and efficacy of the biosimilars. The regulatory pathway used for the 
approval of biosimilars by regulatory health authorities must address 
the characteristics of biosimilars that discriminate them from generic 
drugs, or more broadly, the way in which biologics differ from NCE-
based drugs,therefore, these regulatory bodies around the globe have 
devised various policies for the same. Both general and the product-
specific guidelines have been established by the WHO, FDA, EMA, 
TGA, and Health Canada while some take reference from the already 
developed guidelines some have formulated their own versions to 
select research sites strategically to optimize overall development 
timelines and achieve registration goals. The challenges such as lack of 
resources, unavailable reference product, quality issues, and selecting 
the manufacturing site are still to be addressed. Looking toward the 
future, there is a trend toward harmonization of reference product 
requirements and an era of opportunities.
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